Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries
| Autor: | Susanne Qvitzau, Andrew J. K. Östör, Alan Reynolds, Rose-Marie Lindkvist, Mats Ekelund, Per Larsson, Robert J. Moots, Pentti Järvinen, Anne G. R. Loft, Danuta Kielar |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Employment Male medicine.medical_specialty Sick Leave/statistics & numerical data Efficiency Immunoglobulin G/administration & dosage Receptors Tumor Necrosis Factor Etanercept Young Adult Indirect costs Antirheumatic Agents/administration & dosage Rheumatology Quality of life Spondylitis Ankylosing/drug therapy Health care medicine Humans Spondylitis Ankylosing Pharmacology (medical) In patient Receptors Tumor Necrosis Factor/administration & dosage health care economics and organizations Aged Work productivity business.industry Health Care Costs Middle Aged humanities Treatment Outcome Antirheumatic Agents Immunoglobulin G Sick leave Quality of Life Physical therapy Female Sick Leave Open label business medicine.drug |
| Zdroj: | Moots, R J, Ostor, A J K, Loft, A G R, Järvinen, P, Larsson, P, Ekelund, M, Reynolds, A, Kielar, D, Lindkvist, R-M & Qvitzau, S 2012, ' Reduction of direct and indirect costs in patients with AS receiving etanercept : results from an open-label 36-week extension of the ASCEND study in four European countries ', Rheumatology, vol. 51, no. 2, pp. 393-6 . https://doi.org/10.1093/rheumatology/ker404 |
| ISSN: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/ker404 |
| Popis: | OBJECTIVE: To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL).METHODS: A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36-52 weeks with ETN 50 mg s.c. once weekly. Analysis included direct costs (transformed out-patient and in-patient care elements), indirect costs (sick leave and lost working days), efficacy and QoL.RESULTS: Annualized direct and indirect costs decreased (55.5%, P ≤ 0.008) during ETN treatment, as did out-patient and in-patient episodes (physiotherapist/physician visits, P = 0.012). Work productivity and QoL increased.CONCLUSION: ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS. Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|